Drugs /

hla-a2 restricted tumor antigen peptide vaccine

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for hla-a2 restricted tumor antigen peptide vaccine

Hla-a2 restricted tumor antigen peptide vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating hla-a2 restricted tumor antigen peptide vaccine, 1 is phase 1 (1 open).

HLA-A*02 Positive is the most frequent biomarker inclusion criterion for hla-a2 restricted tumor antigen peptide vaccine clinical trials.

Ependymoma is the most common disease being investigated in hla-a2 restricted tumor antigen peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hla-A2 Restricted Tumor Antigen Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hla-a2 restricted tumor antigen peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.